A pre-commercial client was developing a targeted small molecule formulation for serious heart disease where patients are commonly misdiagnosed, leading to skepticism over published disease prevalence. Our client posed three challenges: 1) what is the potential volume of undiagnosed patients?; 2)what are the comparative profiles of known and predicted, undiagnosed patients?; and 3) which healthcare providers are managing the potential undiagnosed?

IPM.ai developed 4 scenarios, selected the optimal curve of likely patients and created an exhaustive set of criteria to size our client’s market. We also provided insights on known patients, including procedure codes highly predictive of upcoming diagnoses, HCP target lists including specialties outside of cardiology that were challenging to locate and prioritize and a revised estimate of disease prevalence, all of which is being utilized in the planning and forecast process.